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Abstract
Background: After intravenous delivery of the adenoviral vector into rats or mice, 95–99% of the
encoded protein is produced in the hepatocytes. We observed, as have others, that the early
expression levels of the vector encoded protein vary, greatly, within a species, from one animal
strain to another. This study was initiated to determine the molecular mechanism causing the
difference: hepatic transfection, transcription or translation. For this purpose different doses of
Ad5 luciferase and Ad5 LacZ were intravenously injected into Brown Norway rats and Wag/Rij
rats, two strains that differ by a factor of 10 in encoded protein levels. The proportion of LacZ
positive hepatocytes, the adenoviral DNA, specific transgenic RNA and luciferase protein were
compared in the two strains.
Results: The number of transduced hepatocytes and the amounts of Ad5 DNA in the livers was
similar in both strains, whereas the Brown Norway rats produced 8 to 10 times more of both
vector encoded proteins and of transgene mRNA than the Wag/Rij rats.
Conclusions: It is concluded that the difference between strains in vector encoded protein
expression is due to different transcriptional events. No evidence was obtained to suggest that the
differences are related to liver damage influenced by vector toxicity or immune reactions.
Background
In the course of studies involving intravenous adenoviral
gene transfer, we observed a 10 fold difference in plasma
levels of the encoded proteins between two of the rat
strains employed: the Wag /Rij and the Brown Norway.
These differences were observed for several vector encod-
ed proteins as soon as 2 days after gene delivery and were
maintained for one month, after which the levels declined
slowly to background. Other investigators described dif-
ferences of the same order of magnitude between mouse
strains in expression of transgenes encoding α1-antit-
rypsin [1], interleukin-12 [2], and human endostatin [3].
These differences in transgene expression between inbred
species may have clinical implications, as differences be-
tween inbred strains are considered to reflect differences
between individuals of an outbred species.
Consequently, the therapeutic efficiency of a transgene
could drastically vary from one patient to another. So far,
a satisfactory explanation for such strain differences has
not been provided. Most authors have attributed the dif-
ference of plasma levels of vector encoded protein to im-
mune reactions against the protein or against the vector
[4,5]. However, the kinetics of the vector encoded pro-
teins in the plasma do not support regulation by an adap-
tive immune reaction, as the strain difference is manifest
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as early as 2 days after administration of the vector. Innate
humoral immunity, e.g. the presence of neutralising anti-
bodies against the vector can also be excluded as the cause
of the difference because such antibodies are not present
in naïve rats. An innate cellular immune reaction directed
against the infected liver cells is also an unlikely explana-
tion because plasma transaminase levels [6] – a marker of
hepatolysis – though somewhat elevated, are not different
in the two strains.
The main organ infected by an adenovirus following iv in-
jection is the liver [7,8]. Others and we find that the liver
is producing 95–99% of the vector encoded protein after
intravenous delivery of recombinant adenoviral vectors.
The global process from liver cell infection to protein pro-
duction is commonly described as adenoviral permissive-
ness of the liver. In this study we investigated which one
of these three processes (transfection, transcription, trans-
lation) is pivotal for the strain difference in transgene
expression.
Secreted vector encoded proteins are not suitable to inter-
pret the early manifestation of transgene expression, as
plasma levels are highly dependent on the pharmacoki-
netic properties of the encoded proteins. Therefore, we
employed adenoviral encoded marker genes, the intracel-
lular Luciferase (Luc) and the nuclear β-Galactosidase
(LacZ). The luciferase activity of the whole liver is a meas-
ure of vector encoded protein expression in that organ
while the LacZ staining of hepatocytes provides informa-
tion on the proportion of liver cells infected. Furthermore,
we determined the amount of Ad5 DNA and of transgene
mRNA in the liver as measures of the adenoviral infection
of hepatic cells and of transgene transcription respectively.
Results
Intravenous injection of Ad5 vectors in different rat strains 
results in different levels of early transgene expression
Intravenous administration of a fixed dose of Ad5 vector
either expressing the human endostatin gene, or the gene
for mhATF-BPTI resulted in clear 10-fold difference in the
plasma levels of both proteins between Brown Norway
and Wag/Rij rats (Fig. 1 and 2). This difference was detect-
ed as soon as 3 days after the vector administration and
persisted during the first 6 weeks, subsequently the plas-
ma levels of both proteins slowly decreased to undetecta-
ble levels in 2 to 3 months. To investigate whether the
livers of the 2 rat strains differ in their permissiveness for
Ad5 or if this phenomenon could be explained by differ-
ences in the hepatocyte secretion capacity, we administrat-
ed Ad5 vector carrying the gene for Luciferase (Ad5 Adapt
Luc), a protein that is not secreted.
Measurements of Luciferase transgene activity in various
organs, following iv administration of the vector, con-
firmed the observations from other research groups [7,8]
that in rodents 95–99% of virus infection and subsequent
transgene expression occurs in the liver (Table 1).
Next, we determined luciferase activity in the liver of
Brown Norway and Wag/Rij rats 2 days after intravenous
injection of 109 iu, 3.109 iu, or 1010infectious units (iu) of
Ad5 Adapt Luc. The results depicted in the Fig. 3 seem to
reflect those observed with ATF-BPTI and endostatin nam-
ing a 10-fold difference between Wag/Rij and Brown Nor-
way rats. These experiments with the non-secreted
luciferase vector encoded protein confirmed that the two
rat strains have a very different liver response to the re-
combinant adenovirus. Since the levels of mhATF-BPTI
and endostatin reached a plateau about 7 days after vector
delivery both in the Brown Norway and in the Wag/Rij
rats, we also determined the luciferase activity in the liver
7 days post intravenous administration of the Ad5 Adapt
Luc. As shown in figure 4, roughly the same values were
obtained at the 2 time points, which reflect the kinetics of
the plasma concentrations of the secreted proteins ATF-
BPTI and endostatine.
β-Galactosidase expression in hepatocytes from Brown 
Norway and Wag/Rij rats
To explore whether differences in the number of trans-
duced hepatocytes could account for the observed differ-
ences in transgene expression levels, we injected different
doses (109 iu, 3.109 iu and 1010 iu) of Ad5 Adapt LacZ
into the tail vein of the rats. Histological inspection of the
stained sections allowed an estimation of the proportion
of transduced liver cells. Animals were sacrificed after 2
days, liver sections were prepared and stained with X-gal.
The liver sections revealed an inhomogeneous distribu-
tion of transduced cells. In both rat strains hepatocytes
were the sole cell type expressing the β-Galactosidase.
Both the number of stained cells and the staining intensity
was highest near the interlobular (portal) vein and de-
clined gradually towards the centro lobular area (Fig. 5).
The percentage of blue nuclei was roughly proportional to
the amount of infectious units administered and did not
differ significantly between the two strains (Table 2).
However, overall, the intensity of the nuclear LacZ stain
was 8 to 9 times higher in the Brown Norway than in Wag/
Rij liver sections as determined by computer-assisted anal-
ysis of the histological section (Fig. 6). These findings sug-
gest that although the protein production is significantly
higher in the Brown Norway rats, the number of infected
cells is roughly similar for both rat strains. Still the
number of infectious particles per hepatocytes might be
higher in the Brown Norway rats. However the number of
iu can never be 10 time higher because that would require
at least 10 × the number of hepatocytes (1.8 109) = 1.8
1010, and the dose administered was 1010 iu.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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The number of recombinant adenovirus copies in the liver
Real-time PCR was employed to quantify the copy
number of the adenoviral genome in the hepatocytes of
rats from the previously described experiments that re-
ceived graded doses of Ad5 Adapt Luc, or of Ad5 Adapt
LacZ. As listed in Table 3, the number of adenoviral copies
per liver was similar in the Brown Norway and Wag/Rij
rats for both vectors. Roughly, there is a linear relation be-
tween the Ad5 DNA detected and the dose of adenoviral
vector administered. In the case of LacZ, the deviation
from the linearity is not statistically significant.
These results shows that recombinant Ad5 infect hepato-
cytes of both rat strains with similar efficiencies. Thus, the
observed differences in levels of vector encoded protein
must be due to differences in transcription (CMV-promot-
er activity), RNA stability, RNA translation, or post trans-
lational processes.
Liver damage
Considering that the local inflammation of the liver may
significantly increase the synthesis of certain proteins, it
could be that the difference in transgene expression ob-
served is a consequence of different inflammatory reac-
tions in the two strains. To eliminate the possibility that
the difference found in the Brown Norway rats in encoded
protein is due to a global increase in protein synthesis, the
total amount of liver protein was determined after differ-
ent vector doses and time points. It was found to be simi-
lar in both strains and not significantly elevated from the
basal line (Table 5).
Adenovirus particles in apoptotic hepatocytes or phagocy-
tosed by immune cells would not contribute to the luci-
ferase production. However, to exclude that a massive
hepatitis or a severe inflammatory infiltrate in the liver is
causing the difference of luciferase expression, the inflam-
matory infiltration and pathological changes were
Figure 1
Plasma levels of ATF-BPTI in Brown Norway (black squares) and in Wag/Rij (open circle) after iv injection of 1010 iu Ad5 Adapt 
mhATF-BPTI. Ten animals per group, data are expressed as mean ± SD.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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Figure 2
Plasma levels of endostatin in Brown Norway (black squares) and in Wag/Rij (open circle), after iv injection of 1010 iu Ad5 
Adapt hEndostatin. Ten animals per group, data are expressed as mean ± SD.
Table 1: Percentage of total luciferase activity per organ measured in the Brown Norway and Wag/Rij rats 2 days after intravenous 
administration of 3.109 iu of Ad.Adapt.luc virus. The luciferase activity is expressed in RLU / mg protein. Data are expressed as mean ± 
SD. Fresh organs were weighted and the mean value is expressed in grams / 100 grams body weight. The muscle mass was estimated 
from the human situation as 40% of total body mass. The bone marrow was previously measured.
Organs Weight (g / 100 g) Brown Norway (n = 14) Wag/Rij (n = 6)
Liver 3.4 97.91 ± 2.35 96.88 ± 4.76
Spleen 0.3 1.93 ± 2.05 1.99 ± 1.52
Heart 0.5 0.072 ± 0.04 0.06 ± 0.05
Lung 0.8 0.037 ± 0.04 0.04 ± 0.005
Kidney 1.1 0.001 ± 0.008 0.03 ± 0.02
Muscle 40 0.005 ± 0.06 0.89 ± 0.92
Brain 1 0.003 ± 0.006 Not done
Bone Marrow 1 0.028 ± 0.01 0.11 ± 0.23BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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determined in the liver of the two rat strains (Table 5). The
damage scoring shows that there is no difference of toxic-
ity or infiltration 2 days after vector delivery and that the
difference in transgene expression persisted even when a
low dose of adenovirus that caused hardly any inflamma-
tion was injected. At 7 days after the injection, the Brown
Norway rats showed a significant higher liver damage and
infiltration than the Wag/Rij rats. However, this deviation
of the toxicity between the two strains was not accompa-
nied by an increase in the difference of transgene expres-
sion. Seemingly, the difference in transgene expression,
seen 2 days as well as 7 days after vector administration, is
due to processes that occur after the penetration of the vi-
rus into the cells.
Northern Blotting of the Luciferase transcript
To investigate whether an intrinsic difference exists in
transcription efficiency or in translation efficiency, the
amount of the luciferase mRNA present in the liver of rats
was determined after administration of 1010 iu Ad5 Adapt
Luc intravenously. As depicted in Fig. 7, the northern blot
of the liver RNA shows about 10 times more luciferase
mRNA in the liver of the Brown Norway rats than in the
Wag / Rij rats. These findings leave open only two options
to explain the difference in protein levels observed, name-
ly an intrinsic difference in transcription efficiency (under
the CMV promoter) or a difference in RNA stability.
Discussion
It has been suggested that, after iv administration, low
dose intravenous adenoviral vectors are taken up by
Kupffer cells and degraded quickly within a few hours
[1,9] whereas higher doses saturate these cells and the sur-
plus productively transduce hepatocytes. Therefore, we
used doses (109 iu – 1010 iu) that are in the linear part of
the dose response curve and well above the threshold ef-
fect. In both rat strains, 2 days after intravenous delivery
of the vector, the β-Galactosidase was observed only in the
Figure 3
Luciferase expression in the liver of the Wag/Rij and Brown Norway rats. A: luciferase activity determined 48 hours after iv 
injection of 109 iu (gray bars, n = 6), 3 109 iu (striped bars, n = 6), and 1010 iu (black bars, n = 12) Ad5 Adapt Luc. Data are 
expressed as mean ± SD.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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hepatocytes. Consequently, it may be concluded that the
bulk of the adenoviral genomes in the liver is localized in
the hepatocytes.
After correction for the extraction efficiency of DNA, an
average of 2.6 109 copies of vector genome were detected
in the livers following administration of 1010  iu Ad5
Adapt LacZ. At this dose 75% of the hepatocytes stained
positive for β-Galactosidase. It is estimated that the liver
of a 350 g rat contains about 1.8 109 hepatocytes [10].
Thus the average number of infectious units per hepato-
cyte is about 1.5. It is assumed that the infection of hepa-
tocytes by the adenoviruses is a random event following
the Poisson distribution. Then, this event will occur at
least one time in 75% of the cases when the expected
number of occurrences is 1.5. As about 75% of the hepa-
tocytes stained blue following injection of 1010 iu, an
hepatocyte will stain blue if it has incorporated one copy
of the vector. Poisson probability calculations show also
that under these conditions the infection occurs twice in
40% and three times in 20% of the hepatocytes. This var-
iation in the number of adenoviral copies per cell can ex-
plain the variation of the staining intensity per cell within
one liver, from light to dark blue.
In each of the vectors used in this study the transgene was
under the control of the CMV immediate early promoter.
It was determined, by Norther Blots, that the amount of
transgenic mRNA was also different in both rat strains.
Thus, the difference in vector encoded protein production
found is due to difference in transgene transcription or
difference in RNA stability.
As expected, a difference in protein levels was observed
following 3 different doses of the vector 109, 3 109 and
1010 iu. However, the lower the dose, the smaller is the
difference of protein expression between the two rat
strains. This might be explained by a saturation of the
transgene expression machinery in the Wag / Rij hepato-
cytes at the higher doses.
Figure 4
Luciferase expression in the liver of different rat strains after iv injection of 1010 iu Ad5 Adapt Luc. The luciferase expression 
was determined two days (gray bars) and seven days (black bars) after virus injection. Determination after 2 or 7 days reveals 
a 10-fold difference (p = 0.0001, Scheffé post-hoc test.) in luciferase activity between the Wag/Rij and the Brown Norway. Six 
animals per group, data are expressed as mean ± SD.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
Page 7 of 14
(page number not for citation purposes)
Figure 5
The "porto-cava" gradient of the transgene expression viewed on a 50 × magnification field of liver section stained for X-Gal 
and counterstained with red. The livers were collected 2 days after iv injection of 1010 iu Ad5 Adapt LacZ A: Brown Norway 
rat. B: Wag/Rij rat. The white arrow points to a interlobular (portal) vein. The black arrow points to a central vein in the cen-
tro-lobular area.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
Page 8 of 14
(page number not for citation purposes)
Figure 6
Comparison of histological sections of the liver of Brown Norway and Wag/Rij rats 2 days after iv injection of 1010 iu Ad5 
Adapt LacZ. The staining was carried out on 10-µm thick frozen sections. Four sections per slide, each slides represent one 
rat.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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Table 2: Percentage of hepatocytes expressing β-Galactosidase after iv injection of Ad5 Adapt LacZ. The blue nuclei were counted on 
a 200 × magnification field of a liver section. Four fields per section, 4 sections per animal. Data are expressed as mean ± SD
Percentage of blue hepatocytes
Wag/Rij Brown Norway
Dose N Portal area Centro-lobular area Portal area Centro-lobular area
1010 iu 3 82 ± 5.1 69 ± 4.6 92 ± 4.5 74 ± 3.0
3.109 iu 3 37 ± 11.3 32 ± 11.3 57 ± 20.5 49 ± 15.6
109 iu 6 10 ± 0.7 8 ± 0.7 19 ± 4.6 14 ± 2.5
Table 3: Number of Adenoviral DNA copies per liver determined by duplex real time PCR. This table refers to the animals depicted in 
Fig. 3 and in Table 2. The number of DNA copies was determined from a small weighted mass of liver and then extrapolated to the 
total liver mass. Data are expressed as mean ± SD
Adenoviral copies (× 107) / liver
Dose N Wag/Rij Brown Norway
Ad5 Adapt Luc 1010 iu 6 160 ± 80 130 ± 50
3.109 iu 6 17 ± 11 19 ± 12
Ad5 Adapt LacZ 1010 iu 6 159 ± 50 161 ± 51
3.109 iu 3 45 ± 12 28 ± 8
109 iu 3 5.2 ± 0.7 9.4 ± 3
Table 4: Criteria for grading the liver lesions The pathological changes were graded on 3 transversal sections of the right liver lobe. The 
total damage score is a compilation of scores of apoptosis, vacuolar changes, nuclear condensation, anisokaryosis, megalocytosis, 
mitosis, and inflammation. All scores are ranging from 0 to 3. The vacuolar change was defined as clear cytoplasm for more the 90% of 
the nuclear circumference.
Score
01 2 3
Apoptosis Number of apoptotic 
cells / bodies in 10 random 20 × 
magnification fields
0–1 <5 5–13 >13
Vacuolar change Percentage of 
hepatocytes affected.
No or sporadic 10 % 10–50% > 50%
Condensed nuclei Percentage 
of hepatocytes affected.
No or sporadic 10 % 10–50% > 50%
Anisokaryosis Normal variation. 5–10% of the nuclei with 2 
time the normal size
10–30% of the nuclei with 
2 time the normal size
10–30% of the nuclei with 
3 time the normal size
Megalocytosis No or sporadic 3–10 / 2 sections > 10 / 2 sections > 30% of hepatocytes
Mitosis Number of mitosis in 10 
random 20 × magnification fields
0–1 <5 5–13 >13
Inflammation I Inflammation in 
the Periportal Space (PS)
Normal background Few PS with mild inflam. Many PS with mild inflam.
Or
Few PS with moderate 
inflam
Many PS with moderate 
inflam.
Or
Few PS with severe inflam.
Inflammation II Diffuse or 
multifocal inflammation in sinusoid 
and central veins
Normal background Increase of inflammatory 
cells
Aggregates of inflamma-
tory cells
Aggregates of inflammatory 
cells obscuring the liver 
architectureBMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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The different protein expression in Wag / Rij and Brown
Norway rats was observed with 4 different transgenes (Lu-
ciferase,  β-Galactosidase, endostatin and mhATF-BPTI)
and at several different doses. Our experiments localised
the mechanism of this difference at the transcriptional lev-
el and disqualified the hypothesis based on immunologi-
cal induced death of the infected cells. Nevertheless, the
differences of transcription efficiency observed between
the two rat strains might be due to different cytokine pro-
duction following the adenoviral infection. It was shown
that the adenoviral infection of the liver activates the in-
nate immunity with increase NK cells and cytokines pro-
duction (INF-γ, TNF-α, IL-12, IL-6) [11–14]. Further,
differences of this activation between mouse strains were
associated with variation in adenovirus transgene
expression [11,13]. However it was demonstrated that no
activation of the innate immunity and that no difference
of transgene expression could be observed before the sev-
enth day after the adenoviral administration [13]. Further-
more the decrease of transgene expression after activation
of the innate immunity following i.v. administration of
adenovirus was due to decrease of the number of infected
cells and a corresponding diminution of the viral DNA in
the liver [15]. Our results do not show such results. How-
ever, in such perspective we measured the serum level of
INF-γ in both rat strains 2 days after the vector administra-
tion and no difference could be observed (60 ± 14 pg / ml
in the Wag/Rij rats versus 65 ± 18 pg / ml in the Brown
Norway rats). Nevertheless, difference of intracellular cy-
tokine response to the adenoviral infection might explain
the difference in transcription efficiency.
In general, differences between inbred strains are consid-
ered to reflect differences between individual members of
outbred species. If the variation observed in the rat strains
described here would hold for individual humans, the
therapeutic efficiency of gene transfer could drastically
vary from one patient to another after systemic adminis-
tration of adenoviral vectors.
Methods
Animals
Pathogen-free inbred male Wag/Rij and Brown Norway
rats, weighing 300 to 350 gr were purchased from Harlan,
The Netherlands. All animals were fed ad libitum with
laboratory chow and water and were kept under standard
laboratory conditions. For assay of plasma transaminase
(ALT), hEndostatin, and mhATF-BPTI, rats were
anaesthetised with isoflurane and bled by tail vein
puncture and the blood was collected in EDTA tubes. All
animal procedures were performed in accordance with the
official guidelines after obtaining permission of the
animal welfare committee. Measurements of ALT were
performed according to standard clinical procedures.
Table 5: Liver damage caused by adenoviruses. The liver lesions were assessed, as described in table 4, two and seven days after the 
intravenous injection of the adenoviral vector. The total liver inflammation and damage scores range from 0–6 and 0–24 respectively. 
The transaminase (ALAT) was measured in the serum on day 2 and 7. The normal value of ALAT, measured in ten healthy animals, is 
59 +/-19 IU/l. 6 animals per group. The values indicate the mean ± sd
High dose (1010 iu) Low dose (109 iu)
Brown Norway Wag / Rij Brown Norway Wag / Rij
Total liver inflammation
• Day 2 0.50 ± 0.31 0.41 ± 0.37 0.58 ± 0.20 0.41 ± 0.20
• Day 7 3 ± 1.0 1.3 ± 0.4 1.08 ± 0.49 0.66 ± 0.25
Total liver damage
• Day 2 2.6 ± 0.5 2.1 ± 0.7 0.8 ± 0.4 0.5 ± 0.2
• Day 7 14.5 ± 2.6 9.3 ± 1.1 4.9 ± 0.8 2.7 ± 0.7
ALAT (IU/l)
• Day 2 63 ± 15 58 ± 16 44 ± 22 55 ± 19
• Day 7 218 ± 33 104 ± 17 86 ± 27 86 ± 27
γGT (IU /l) day 2 4.5 ± 0.6 4.8 ± 0.5 Not done Not done
LDH (IU /l) day 2 837 ± 249 741 ± 356 Not done Not done
INF-γ (pg / ml) day 2 60 ± 14 65 ± 18 Not done Not done
Liver proteins (mg/g tissue)
• Day 2 150 ± 21 150 ± 33 110 ± 21 120 ± 18
• Day 7 167 ± 32 177 ± 31 130 ± 42 136 ± 25
Luciferase (104 RLU/mg 
protein)
• Day 2 441 ± 158 31 ± 27 1.2 ± 0.3 0.25 ± 0.12
• Day 7 451 ± 128 44 ± 29 1.5 ± 0.5 0.27 ± 0.17BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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Figure 7
Northern Blots. Northern blot of the total RNA extracted from the liver of both rat strains. The hybridisation was done with 
a radioactive probe specific for the luciferase mRNA and then with a probe specific for the β-Actine mRNA. Lane 1–8: Wag/Rij 
rats, lane 1–2 animals injected with Ad5 Adapt Empty, lane 3–8: animals injected with Ad5 Adapt Luc. Lane 9–16: Brown Nor-
way rats, lane 9–10 animals injected with Ad5 Adapt Empty, lane 11–16: animals injected with Ad5 Adapt Luc. The quantifica-
tion of the signals with the phosphorimager shows that there is no difference in the quantity of β-actine transcript whereas 
there is about 10 times more luciferase transcripts in the liver of the Brown Norway rats than in the Wag/Rij rats. Means val-
ues +/- sd expressed in arbitrary units are depicted on the gel.BMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
Page 12 of 14
(page number not for citation purposes)
Adenoviral vectors
Recombinant adenovirus vectors were generated in
PER.C6™ cells by homologous recombination between an
adapter plasmid (pAdapt) and the E1 deleted Ad 5 DNA
plasmid as described elsewhere [16]. The expression cas-
sette contains a CMV promoter and SV40 poly A signal. As
a result of the absence of sequence overlap between the
Adapt plasmid and the Ad5 E1 sequences integrated into
the genome of PER.C6, the vector stocks used in this study
did not contain replicative competent adenovirus (RCA)
[17].
The Ad5 Adapt mhAB encodes for a murinised form of the
human ATF-BPTI (mhAB)[18]. In this construct the
mhATF-BPTI, is preceded by the native secretion signal
peptide of the human urokinase. The human endostatin
coding sequence (InvivoGen, CA, USA) was cloned in the
Ad5 Adapt shuttle vector. The encoded endostatin corre-
sponds to the 183 residue of the human endostatin de-
scribed by O'Reilly et al (1997) with an intact N-terminus
(HSHRDFQ...), preceded by the secretion signal peptide
of the human IL-2. The Ad.Adapt.Luc and the
Ad.Adapt.LacZ are recombinant adenoviral vectors in
which the E3 region of Ad5 is retained and the gene of in-
terest (luciferase or LacZ) replaces the E1 region. The Ad5
Adapt empty is identical to Ad5 Adapt mhAB except that
it does not encode any transgene.
All vectors were produced on PER.C6™ using standard
procedures [17]. Infectious units (iu)/ml were determined
by end point cytopathogenic effect (CPE) assay on 911
cells [19]. Viral particles were determined by HPLC [20].
The particle to infectious unit ratio was always lower than
10. A single batch per vector was used in all experiments.
Liver lysate and Luciferase activity assay
Rats were sacrificed by an overdose of isoflurane and
whole organs were dissected out, frozen in liquid nitrogen
and stored at -80°C. Organs were homogenised in phos-
phate buffered saline pH 7.8 using a blender. To lyse the
cells, DTT (SIGMA, The Netherlands) (1 mM) and Triton
x-100 (0.1%) (Merck, The Netherlands) were added. After
centrifugation at 10,000 rpm for 10 min, 20 µl of the su-
pernatant was added to 100 µl of luciferase assay substrate
(Promega, The Netherlands). Relative light units (RLU)
were determined for 30 s using a luminometer (Lumat
951, Wallac, Belgium). The amount of protein in the
extracts was determined using a commercial kit (Bio-Rad
laboratories, The Netherlands) based on the Coomasie
brilliant blue G250 binding assay developed by Bradford
[21]. The level of luciferase activity in the tissue homoge-
nates was expressed in RLU / mg protein. The background
level of this assay is <1000 RLU/mg protein and was de-
fined by measuring luciferase activity in organs of non
treated rats.
LacZ expression assay
Forty-eight hours after Ad5 Adapt LacZ administration
rats were sacrificed and organs were removed and cut in 2
mm sections. Sections were fixed in 10% phosphate
buffered formalin (pH 7.0) for 60 min at room tempera-
ture and incubated overnight in 0.5 M sucrose. The sam-
ples were subsequently frozen in liquid nitrogen. Ten µm
thick frozen sections were prepared and stained with 5-
bromo-4-chloro-3-indolyl-β-galactopyranoside (X-gal)
solution (Molecular Probes, The Netherlands) overnight
at 37°C. Finally, sections were counterstained with Hema-
toxylin-Phloxin-Safran. The number of blue nuclei in each
section was determined on digitalised photographs of
four 20 × magnification fields with the interlobular vein
in the centre (designated portal area) and of four fields
centred on the central vein (called centro-lobular area).
These two areas were slightly overlapping. The resolution
of the photographs, which were processed in Adobe Pho-
toshop 5.0, was 600 dots per inch (dpi). Cells were con-
sidered positive when a blue staining was seen in the
nucleus. The total number of hepatocytes per field was de-
termined by dividing the surface of the tissue section by
the average surface of a hepatocyte. The surface of the lu-
men of large vessels was subtracted from the total surface
of the tissue section. The average surface of the hepato-
cytes was determined by ten measurements of mononu-
clear hepatocytes per field. The surface measurements
were performed with the NIH Image 1.62 software. It was
shown in rats that binuclear hepatocytes have double the
volume of mononuclear hepatocytes and that the
extrahepatocytic space volume was 15% of the total liver
volume [10].
To compare β-Galactosidase expression levels in the livers
of Wag/Rij and Brown Norway rats, frozen livers were cut
into sections with a thickness of 5, 10, 15, 20, 25, 30, 35,
40, 45 and 50 µm. Whole sections were scanned at 600
dpi under TIFF format and analysed in Adobe Photoshop
6.0. We quantified the blue staining intensity by perform-
ing the histogram of the luminosity and of the four col-
ours on the whole liver section. Matching the histograms
of a Brown Norway section to a Wag/Rij section with dif-
ferent thickness determine the relative liver β-Galactosi-
dase intensity of the two strains.
Elisa assays
An mhATF-BPTI enzyme-linked immunoabsorbent assay
(ELISA) was developed by Dr. P. Quax (Toegepast Natuur-
wetenschappelijk Onderzoek institute), using a mono-
clonal antibody specific for the ATF as the capture
antibody and a polyclonal antibody directed against BPTI
as the detector antibody [18]. As a standard we used me-
dium of Ad5 Adapt mhAB infected CHO cell culture in
which the mhATF-BPTI concentration was determined by
an urokinase ELISA. Secretion of human endostatin inBMC Molecular Biology 2003, 4 http://www.biomedcentral.com/1471-2199/4/4
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plasma was routinely determined using a commercial
ELISA kit (InvivoGen, CA, USA) according to the manu-
facturer procedure. INF-γ levels in rat sera were measured
by an ELISA kit (BioSource Netherlands, B.V., The
Netherlands).
Real Time PCR analysis
The amount of adenoviral genomes per cell was deter-
mined by a multiplex real-time polymerase chain reaction
[22]. Real-time PCR is based on the 5'-3' nuclease activity
of AmpliTaq Gold polymerase, which allows it to cleave
fluorogenic probes resulting in fluorescence. The amount
of fluorescence obtained during the PCR reaction is repre-
sentative to the amount of amplified DNA.
Total DNA of transduced rat organs was extracted by using
a DNeasy Tissue Kit (Qiagen). The kit efficiency was veri-
fied by measuring the recovery of plasmid DNA mixed
from a liver lysate. We confirmed that 80% of the total
DNA can be extracted from liver samples, as described by
the manufacturer. To amplify the adenoviral DNA, specif-
ic primers (Ad5Clip-F: 5'CGACGGATGTGGCAAAAGT3'
and Ad5Clip-R: 5'CCTAAAACCGCGCGAAAA3') were de-
signed by using the Primer Express Software (Perkin-Elm-
er, Foster City, CA, USA). A fluorogenic probe (Ad5Clip-
Pr: 5'-VIC-CACCGGCGCACACCAAAAACG-TAMRA-3')
was also designed by the Primer Express Software. To
determine the amount of cellular DNA present in the sam-
ple a second pair of primers and a FAM-probe specific for
18S rDNA [22] were used. The PCR reaction mixture con-
sisted of 1 × buffer A (Perkin-Elmer), 3 mM MgCl2, 200
µM dNTPs, 90 nM of each adenovirus primer, 100 nM of
each 18S rDNA primer, 200 nM of each probe, 0.6 U
AmpliTaq Gold polymerase (Perkin-Elmer) and 5 µl of to-
tal DNA sample. As a standard, to determine the amount
of adenoviral genomes and cellular DNA, a plasmid con-
taining approximately 5000 bp of the left part of the Ad5
genome (pAdapt) was mixed with cellular DNA extracted
from A549 cells. The PCR reaction was initiated with a hot
start at 95°C for 10 min and involved 45 cycles of 15 s at
95°C and 1 min at 60°C.
Northern Blotting
The animals were sacrificed 2 days after vector administra-
tion and the liver was immediately collected and snap fro-
zen in liquid nitrogen. The liver samples were cut and
homogenised in Trizol reagent (Gibco Life Technologies)
using a blender. Total RNA was isolated from the liver tis-
sue homogenate by using the method developed by Cho-
moczynski and Sacchi [23]. Briefly, chloroform was added
and the aqueous phase containing the RNA was recov-
ered. RNA was precipitated with isopropyl alcohol and the
pellet was resuspended in RNase free water. The RNA and
DNA content were measured by spectrophotometric
analysis.
The quantity of RNA loaded was 20 µg as determined by
spectrophotometry. The RNA loaded represents a similar
proportion of luciferase mRNA in both strains as the total
concentrations of RNA are similar in the Wag/Rij (6.40 ±
1.43 µg/gr) and in the Brown Norway rats (6.55 ± 1.91 µg/
gr). The RNA was run on a 1% agarose gel and transferred
onto Hybond N+ membrane by overnight transfer. The
RNA was then fixed by UV irradiation. The hybridisation
was performed overnight with one stranded [32P]α-dATF
Luciferase probe (1800 bp). The membrane was exposed
to a X-ray film (Kodak) for 24 h and afterwards the mem-
brane was scanned in a phosphorimager for quantifica-
tion. Then the membrane was stripped 15 min at 65°C
and prehybridised with salmon sperm DNA. Then a sec-
ond hybridisation procedure was performed with the
[32P]α-dATF β-actine probe.
Pathology
The scoring of the liver damage was performed in Wag/Rij
and Brown Norway rats 2 and 7 days after the intravenous
injection of adenoviral vectors. The liver pieces were fixed
in formalin 10%, embedded in paraffin and sections of 10
µm were stained with haematoxylin and eosin. The total
damage score is a compilation of scores of apoptosis, vac-
uolar changes, nuclear condensation, anisonucleosis,
megalocytosis, mitosis, and inflammation (Table 4).
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